Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1279-1285

  Abramson, Vandana Gupta ^a   Troxel, Andrea B ^a   Feldman, Michael ^a   Mies, Carolyn ^a   Wang, Yan ^a   Sherman, Lauren ^a   Mcnally, Sara ^a   Diehl, Alan ^a,b   Demichele, Angela ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Cyclin D1; Cyclin D1b; Cyclin dependent kinase inhibitor; Recurrence

Indexed keywords

CYCLIN D1; CYCLIN D1B; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; THYROXINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE RISK; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL TECHNIQUE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; CYCLIN D1; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN ISOFORMS; RISK FACTORS; RNA, MESSENGER;

EID: 77953732182     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer Statistics, 2004. CA Cancer J Clin 54(1): 8-29, 2004.
2. Carter CL, Allen C and Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181-187, 1989.
3. Sunderland MC and McGuire WL: Prognostic indicators in invasive breast cancer. Surg Clin North Am 70(5): 989-1004, 1990. (Pubitemid 20358271)
4. Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7: 812-821, 1993. (Pubitemid 23163585)
5. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671, 1994.
6. Donnellan R and Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 51(1): 1-7, 1998.
7. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
8. Sherr CJ: D-type cyclins. Trends Biochem Sci 20: 187-190, 1995.
9. Lin DI, Barbash O, Kumar KGS, Weber JD, Harper JW, Klein-Szanto AJP, Rustgi A, Fuchs SY and Diehl JA: Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF (FBX4-alphaB crystallin) complex. Mol Cell 24: 355-366, 2006.
10. Diehl JA, Zindy F and Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957-972, 1997.
11. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD and Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11: 1005-1011, 1995.
12. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM and Knudsen ES: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278: 30339-30347, 2003.
13. Lu F, Gladden AB and Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63: 7056-7061, 2003. (Pubitemid 37413439)
14. Krieger S, Gauduchon J, Roussel M, Troussard X and Sola B: Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer 6: 238, 2006.
15. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW and Horne CH: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885-891, 1995.
16. Yu Q, Geng Y and Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021, 2001.
17. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL and Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1: 1257-1260, 1995.
18. Wani G, Noyes I, Milo GE and D'Ambrosio SM: Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression. Mol Med 3: 273-283, 1997.
19. Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M and Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994.
20. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU and Diehl JA: Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 27: 1231-1242, 2008.
21. 1 phase in rodent fibroblasts. Genes Dev 7: 1559-1571, 1993.
22. Alt JR, Cleveland JL, Hannink M and Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114, 2000.
23. Wang Y, Dean JL, Millar EDA, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE and Knudsen ES: Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 68: 5628-5638, 2008.
24. Millar EKA, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CES, Witkjewicz A, Musgrove EA, Rui H, LeMarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL and Knudsen ES: Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 28: 1813-1820, 2009.